Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 4, 1996, Pages 391-394

  Ma, Jianguo ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a   Schellens, Jan H M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Carboplatin; Cisplatin; Unbound platinum

Indexed keywords

ALCOHOL; CARBOPLATIN; CISPLATIN; TRICHLOROACETIC ACID;

ARTICLE; DRUG PROTEIN BINDING; PRIORITY JOURNAL;

BLOOD PROTEINS; CARBOPLATIN; CISPLATIN; ETHANOL; HUMANS; PLATINUM; PRECIPITATION; SPECTROPHOTOMETRY, ATOMIC; TRICHLOROACETIC ACID; ULTRAFILTRATION;

EID: 0029974518     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050501     Document Type: Article

References (25)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Withshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748
2. Childs WJ, Nicholls EJ, Horwich A (1992) The opimisation of carboplatin dose in carboplatin dose in carboplatin, etoposide, and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of testis. Ann Oncol 3: 291
3. Cole WC, Wolf W (1980) Preparation and metabolism of cisplatin/serum protein complex. Chem Biol Interact 30: 223
4. Cole WC, Wolf W (1981) Renal toxicity studies of protein-bound platinum (cis). Chem Biol Interact 31: 341
5. Egorin MJ, Jodrell DI (1992) Utility of individualized carboplatin dose alone and in combination regimens. Semin Oncol 19: 132
6. Erkmen K, Egorin MJ, Reyno LM, Morgan R, Doroshow FH (1995) Effects of storage on the binding of carboplatin to plasma protein. Cancer Chemother Pharmacol 35: 254
7. Fournier C, Vennin P, Hecquet B (1988) Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 21: 75
8. Graham RA, Siddik ZH, Hohn DC (1990) Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy. Cancer Chemother Pharmacol 26: 210
9. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Steison LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29: 658
10. Holler E (1993) Mechanism of action of tumour-inhibiting metal complexs. In: Keppler BK (ed) Metal complexs in cancer chemotherapy. VCH Weinheim, p 40
11. Jacobs C, Kaubisch S, Halsey J, Lumb BL, Gosland M, Coleman CN, Sikic BI (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67: 1518
12. Jodrell DI, Egorin MJ Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Googlow JL, Tan S, Wilttshaw E (1992) Relationship between carboplatin exposure and tumour response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520
13. 3H tetrachloro(D, L-trans)1,2-diamminocyclohexane platinum (IV) (tetraplatin) in mice. Drug Metab Dispos 20: 673
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265
15. Ma J, Verweij J, Planting AST, Boer-Dennert M de, Burg MEL van der, Stoter G, Schellens JHM (1994) Pharmacokineticdynamic relationship of weekly high dose cisplatin in solid tumour patients. Proc Am Soc Clin Oncol 13: 133
16. Melvik JE, Dornish JM, Peterson EO (1992) The binding of cis-dichlorodiammineplatinum(II) to extracellular and intercellular compounds in relation to drug uptake and cytotoxicity in vitro. Br J Cancer 66: 260
17. Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bols GJ (1993) Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53: 3730
18. Mustonen R, Hemminki K, Alhonen A, Hietanen P, Kiilunen M (1988) Determination of cisplatin in blood compartments of cancer patients. IARC Sci Publ 89: 329
19. Newell DR, Pearson ADJ, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis U, Pinkerton CR, Stevens MCG (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 11: 2314
20. Schellens JMH, Ma J, Planting AST, Burg MEL van der, Boer-Dennert M de, Stoter G, Verweij J (1995) Individualization of cisplatin chemotherapy using AUC and DNA-adducts in WBC. Proc Am Assoc Cancer Res 36: 1388
21. Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925
22. Siddik ZH, Jones M, Boxall FE, Harrap KR (1988) Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21: 19
23. Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Hart AAM, Groneningen CJ van, Pinedo HM (1986) Pharmacokinetics of free and total platium speces following rapid and prolonged infusion of cisplatin. Clin Pharmacol Ther 39: 136
24. Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37: 162
25. Yoshida M, Khokhar AR, Zhang Y-P, Thai G, Siddik ZH (1994) Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors. Cancer Chemother Pharmacol 35: 38